11th week of 2021 patent applcation highlights part 10 |
Patent application number | Title | Published |
20210077457 | HIGH-DOSE STATINS FOR AGE-RELATED MACULAR DEGENERATION - Methods of using a high-dose statin for treatment of AMD in a patient can be used to regress drusen and/or drusenoid pigment epithelial detachments (PEDs), to prevent atrophy of the RPE and/or one or more photoreceptors, to prevent vision loss and/or improve visual acuity, and/or to prevent progression from dry AMD to wet AMD. | 2021-03-18 |
20210077458 | DIBENZOTHIOPHENE DERIVATIVES AND METHODS OF TREATING CANCER THEREWITH - In one aspect, the present disclosure provides a compound of the formula: (I) wherein the variables are as defined herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein. | 2021-03-18 |
20210077459 | FORMULATION FOR SOFT ANTICHOLINERGIC ANALOGS - Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis. | 2021-03-18 |
20210077460 | FORMULATION FOR SOFT ANTICHOLINERGIC ANALOGS - Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis. | 2021-03-18 |
20210077461 | NEW USE - The present invention relates to methods and pharmaceutical compositions for the prevention or in delaying time to first occurrence of mortality, in particular cardiovascular death, and/or of cardiovascular hospitalizations in a patient suffering from chronic systolic heart failure, comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of an Angiotensin Receptor Neprilysin inhibitor (ARNi) or of a combination of an Angiotensin Receptor Blocker (ARB) with a Neutral Endopeptidase inhibitor (NEPi) or with a NEPi pro-drug to said patient. | 2021-03-18 |
20210077462 | METHOD AND SYSTEM FOR TREATING CANCER - The invention provides a method for treating cancer in which a level of reduced folate carrier (RFC) or folylpolyglutamate synthetase (FPGS) in cancer cells of the biopsy is determined. If the level of RFC or FPGS in the cancer cells is below a threshold value, the cancer is treated with an inhibitor of serine-hydroxymethyltransferase (SHMT)1. If the level of RFC or FPGS in the cancer cells is above the threshold value, the cancer is treated with an inhibitor of SHMT2 | 2021-03-18 |
20210077463 | Methods and Combination Therapy to Treat Cancer - This invention relates to a method of treating cancer by administering a combination therapy comprising a combination of a MEK inhibitor and a PD-1 axis binding antagonist, or a combination of a MEK inhibitor and a PARP inhibitor, or a combination of a MEK inhibitor and a PD-1 axis binding antagonist and a PARP inhibitor to a patient in need thereof. | 2021-03-18 |
20210077464 | NOVEL ANTI-FUNGAL INHIBITORS - Described herein are methods of treating or preventing a fungal infection by administering one or more compounds of the present invention to a subject. The methods of the present invention treat or prevent a fungal infection of | 2021-03-18 |
20210077465 | ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITIS - Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed. | 2021-03-18 |
20210077466 | ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITIS - Disclosed herein are methods for treating or preventing ophthalmic and dermatologic conditions in a patient, including ocular surface conditions such as blepharitis. The methods can include topically administering directly to an ocular surface of one or more eyes of a patient in need of treatment thereof an effective amount of an isoxazoline parasiticide, formamidine parasiticide, or other active ingredient, formulated into an ophthalmic composition, the ophthalmic composition further comprising a pharmaceutically acceptable vehicle. Compositions are also disclosed. | 2021-03-18 |
20210077467 | Methods of Preventing Cardiovascular Events in Residual Risk Dyslipidemic Populations - The present invention provides pharmacological interventions for the treatment of dyslipidemia, and to the reduction of residual risk of cardiovascular disease and adverse cardiovascular events in patients on intense statin use or with well-controlled LDL-C concentrations. In particular, the invention relates to the use of pemafibrate to prevent cardiovascular events in populations at-risk due to risk factors such as type 2 diabetes mellitus with dyslipidemia in spite of intense statin use or well-controlled LDL-C. | 2021-03-18 |
20210077468 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING - Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them. | 2021-03-18 |
20210077469 | PHARMACEUTICAL COMBINATIONS OF EGFR INHIBITORS AND METHODS OF USE THEREOF - The application relates to a pharmaceutical combination of an allosteric EGFR inhibitor of Formula I: (I), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and an ATP-competitive EGFR inhibitor of Formula I′: (I′), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the combination, and a method of treating or preventing a disease in which EGFR plays a role. | 2021-03-18 |
20210077470 | RIFABUTIN TREATMENT METHODS, USES, AND COMPOSITIONS - The invention provides formulations containing highly concentrated solutions of rifabutin and methods of making such formulations. The invention also provides methods of using such formulations to treat a bacterial infection in a subject. | 2021-03-18 |
20210077471 | RIFABUTIN TREATMENT METHODS, USES, AND COMPOSITIONS - The invention provides systems and methods for increased clinical efficacy of rifabutin against | 2021-03-18 |
20210077472 | ANTIBIOTIC COMBINATION THERAPIES - The invention provides antibiotic combination therapies for treating an | 2021-03-18 |
20210077473 | COMPOSITIONS COMPRISING CYTISINE IN THE TREATMENT AND/OR PREVENTION OF ADDICTION IN SUBJECTS IN NEED THEREOF - Methods of treatment of addiction and/or dependence, methods of promoting cessation of various addictions, such as smoking and/or vaping, and methods of promoting a reduction in various addictions, such as smoking and/or vaping, uses of cytisine as an addiction cessation treatment, and dosage regimens for the foregoing are provided. | 2021-03-18 |
20210077474 | FORMULATIONS OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6- -DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CAR- BONITRILE - 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, or a pharmaceutically acceptable salt, amorphous form, polymorph form, or pharmaceutical composition (including solid formulations or liquid formulations) thereof and the use thereof for treating diseases and disorders which can be treated with a RET kinase inhibitor, such as RET-associated diseases and disorders, e.g., proliferative disorders such as cancers, including hematological cancers and solid tumors, and gastrointestinal disorders such as IBS are disclosed. | 2021-03-18 |
20210077475 | COMPOSITIONS COMPRISING CYTISINE IN THE TREATMENT AND/OR PREVENTION OF ADDICTION IN SUBJECTS IN NEED THEREOF - Methods of treatment of addiction and/or dependence, methods of promoting cessation of various addictions, such as smoking and/or vaping, and methods of promoting a reduction in various addictions, such as smoking and/or vaping, uses of cytisine as an addiction cessation treatment, and dosage regimens for the foregoing are provided. | 2021-03-18 |
20210077476 | COMPOSITION OR METHOD INCLUDING (T)EW-7197 FOR TREATING OR PREVENTING CORNEAL ENDOTHELIAL DISEASES - The present disclosure provides a composition for treating or preventing symptoms, disorders, or diseases of the corneal endothelium. The present invention specifically provides a composition which is for treating or preventing symptoms, disorders, or diseases of the corneal endothelium, and includes (T)EW-7197 (N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline), a derivative thereof, a pharmaceutically acceptable salt thereof, or a solvate of any of the foregoing. | 2021-03-18 |
20210077477 | MICROGLIA MODULATORS FOR USE IN TREATMENT OF DEPRESSION - The present invention relates to methods for treating a depression condition in a subject, including administering to the subject at least one microglial modulator or a combination thereof. Further provided are methods using a microglial modulator(s) in combination with non-invasive brain stimulation (NIBS), such as electroconvulsive therapy (ECT). | 2021-03-18 |
20210077478 | METHOD OF COUNTERING RESPIRATORY DEPRESSION VIA ACTIVATION OF NEURONAL HETEROMERIC NICOTINIC ACETYLCHOLINE RECEPTORS - Compounds capable of activating a neuronal heteromeric nicotinic acetylcholine receptor are provided and can be administered in the form of pharmaceutical compositions of the like. Methods for using the compounds for treating, preventing, or ameliorating respiratory depression and overdose induced by an opioid, or other cause of respiratory depression are also provided. Methods of inducing analgesia, anesthesia, or sedation in a subject, while simultaneously treating, preventing, or ameliorating respiratory depression and overdose induced by an opioid, or other cause of respiratory depression are also provided. | 2021-03-18 |
20210077479 | FORMULATIONS OF PIMAVANSERIN - Provided herein are capsules containing pimavanserin, processes for manufacturing said capsule, and pharmaceutical compositions containing pimavanserin. | 2021-03-18 |
20210077480 | NANOPARTICLE FORMULATIONS OF DECOQUINATE IN THE FORM OF SOLID SOLUTION - Hot-melt extrusion for producing solid solution comprising nanoparticle formulation of decoquinate is disclosed. Aqueous phase comprising the nanoparticles of hot-melt extruding products is homogeneous and stable. Provided is the composition comprising the solid solution of decoquinate and a method of hot-melt extrusion for producing this composition comprising the solid dispersion of decoquinate. Furthermore, provided is the solid solution comprising nanosized decoquinate formulation having improved water solubility and enhanced delivery of decoquinate in digestive system for absorption, increasing bioavailability, and the efficacy against malaria at the liver stage. | 2021-03-18 |
20210077481 | PHARMACEUTICAL COMPOSITION - The present invention relates to a therapeutic agent for an ophthalmic disease comprising a vascular endothelial growth factor (VEGF) receptor inhibitor or an epidermal growth factor (EGF) receptor inhibitor in a nanoparticle form, having a property to be retained in a posterior eye tissue when systemically administered. | 2021-03-18 |
20210077482 | CAMPTOTHECIN DERIVATIVES - Disclosed herein are novel cytotoxic compounds, and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this disclosure relates to novel camptothecin derivatives thereof, intermediates thereof, conjugates thereof, and pharmaceutically acceptable salts thereof, which are useful as medicaments, in particular as anti-proliferative agents (anticancer agents). | 2021-03-18 |
20210077483 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2021-03-18 |
20210077484 | ABUSE DETERRENT COMPOSITIONS AND METHODS OF MAKING SAME - This invention relates a therapeutic pharmaceutical composition comprising: a mixture including an opioid; polyethylene oxide in an amount of about 3 to about 40 wt % of the composition; a disintegrant; and a surfactant; wherein the disintegrant is present in an amount sufficient to cause the pharmaceutical composition to exhibit an immediate release profile. | 2021-03-18 |
20210077485 | PHARMACEUTICAL COMPOSITIONS OF NILOTINIB - Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., C | 2021-03-18 |
20210077486 | Method for Treating Diseases Using SMARCA2/4 Degraders - The present invention provides a method of treating a disease or disorder with at least one SMARCA2/4 degrader, in a subject who are responders to such treatment based on the presence of tumor specific alterations described therein. The present invention also provides the methods for treating prostate cancer in the subjects who are likely to respond to treatment with SMARCA2/4 degraders. | 2021-03-18 |
20210077487 | PHARMACEUTICAL COMPOSITION CONTAINING HDAC6 INHIBITOR AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF ITCHING - The present invention relates to a pharmaceutical composition containing an HDAC6 inhibitor as an active ingredient for prevention or treatment of itching. The present invention provides a novel pharmaceutical composition containing, as an active ingredient, an inhibitor for inhibiting an HDAC6 enzyme, and thus can effectively inhibit and treat itching caused by trypsin, tryptase, histamine, antimycin A, chloroquine, or the like. | 2021-03-18 |
20210077488 | LINEAR GLYCOSIDASE INHIBITORS - Compounds of formula (I), wherein A, R, W, Q, L, n and m have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease. | 2021-03-18 |
20210077489 | 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF - The present disclosure relates to a novel compound as a JAK inhibitor, a composition, and an application thereof. Specifically, the present disclosure provides a compound having high JAK inhibitory activity (as represented by formula (I)) or its isomer, solvate, hydrate, pharmaceutically-acceptable salt, and prodrug, and a pharmaceutical composition containing the compound. Also disclosed is a use of the present compound or pharmaceutical composition in preparation of a medicament for treating autoimmune diseases or cancers. | 2021-03-18 |
20210077490 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS - Described herein are compounds that activate pyruvate kinase, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R | 2021-03-18 |
20210077491 | PHARMACEUTICAL COMPOSITION - The present invention addresses the problem of providing a pharmaceutical composition for the prevention and/or treatment of diseases related to pulmonary fibrosis. Provided is a pharmaceutical composition for the prevention and/or treatment of diseases involving pulmonary fibrosis, in which the active ingredient is 3-[2-(5-{[1-(5-ethoxypyrimidin-2-yl)-2-isopropyl-6-oxo-4-propyl-1,6-dihydropyrimidin-5-yl]methyl}pyridin-2-yl)phenyl]-1,2,4-oxadiazol-5(4H)-one, or a salt thereof, or a solvate of these. | 2021-03-18 |
20210077492 | METHODS AND COMPOSITIONS OF TREATING PANCREATIC CANCER - A method of treating pancreatic cancer in a patient in need thereof according to an embodiment includes administering to the patient an effective amount of a pharmaceutical composition comprising NSC232003 (DT1), NSC127716 (DAC), and one or more pharmaceutically acceptable carriers, excipients, or diluents. | 2021-03-18 |
20210077493 | POLYMORPHS OF ARRY-380, A SELECTIVE HER2 INHIBITOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Polymorphs of N4-(4-([1,2,4]triazolo[1,5 -a]pyridin-7-yloxy)-3 -methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are provided herein. Processes for preparing the polymorphs and pharmaceutical composition comprising the polymorphs are also disclosed. | 2021-03-18 |
20210077494 | PHARMACEUTICAL COMPOSITION AND USE THEREOF FOR ISCHEMIA TREATMENT - A pharmaceutical composition for ischemia treatment of a patient includes Sildenafil and a pharmaceutically acceptable carrier. The dosage form of the pharmaceutical composition is gel, transdermal patch, cream or paste. A use of the pharmaceutical composition for ischemia treatment of a patient is disclosed. | 2021-03-18 |
20210077495 | USE OF VIBEGRON TO TREAT OVERACTIVE BLADDER - The present disclosure is directed to a method of treating overactive bladder comprising orally administering to a subject in need thereof an amount of from about 60 mg to about 90 mg (e.g., about 75 mg) of vibegron per day. The present disclosure is also directed to a pharmaceutical unit dosage composition comprising from about 60 mg to about 90 mg (e.g., about 75 mg) of vibegron for oral administration. | 2021-03-18 |
20210077496 | DOSING OF VIBEGRON FOR TREATMENT OF OVERACTIVE BLADDER - The present disclosure is directed to a method of treating overactive bladder comprising orally administering to a subject in need thereof an amount of from about 50 mg to about 100 mg (e.g., about 75 mg) of vibegron per day. The present disclosure also provides a method of treating overactive bladder comprising orally administering to a subject in need thereof a first dosage of vibegron per day for a first period and a second dosage of vibegron per day thereafter. | 2021-03-18 |
20210077497 | COMPOSITIONS AND METHODS FOR TREATING DEMENTIA WITH LEWY BODIES - The present invention provides methods and compositions for treatment of Dementia with Lewy Bodies. | 2021-03-18 |
20210077498 | TRANSIENT PROTECTION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AGAINST IONIZING RADIATION - This invention is in the area of improved compounds and methods for transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC), from the damage associated with ionizing radiation (IR) exposure using selective radioprotectants. | 2021-03-18 |
20210077499 | CHK1 (SRA737)/PARPI COMBINATION METHODS OF INHIBITING TUMOR GROWTH - Herein disclosed are combinations of Checkpoint Kinase 1 (Chk1) inhibitors and PARP inhibitors useful for inhibiting the growth of tumors such as those in patients with cancer. In particular, the combination demonstrates remarkable synergistic effects on cancer cells that are representative models for tumors. Also provided for are methods for treating disorders or diseases mediated or affected by Chk1 and/or PARP activity. | 2021-03-18 |
20210077500 | PIKFYVE INHIBITORS FOR CANCER THERAPY - The present disclosure relates methods for treating a cancer having activated MET or RAS pathway signaling using an inhibitor of PIKfyve, alone or in combination with a MET inhibitor or a RAS pathway inhibitor, and related compositions and methods to identify PIKfyve inhibitor sensitive cancers for targeted treatment. | 2021-03-18 |
20210077501 | COMPOSITIONS FOR PREVENTING OR TREATING UVEITIS - The present invention relates to a pharmaceutical composition for preventing or treating uveitis, containing a compound represented by a formula I, an optical isomer thereof or a pharmaceutically acceptable salt thereof as an effective component, as well as a treatment method using the compound, and use of the compound in the manufacture of a medicament for treating uveitis. The pharmaceutical composition according to the present invention shows an excellent effect of preventing or treating uveitis. | 2021-03-18 |
20210077502 | COMBINATION THERAPY WITH APILIMOD AND GLUTAMATERGIC AGENTS - Provided are compositions and methods related to the use of apilimod in combination with glutamatergic agents for treating neurological diseases and disorders, and for the treatment of cancer. | 2021-03-18 |
20210077503 | METHODS FOR TREATMENT OF PEDIATRIC SYSTEMIC MASTOCYTOSIS - Methods for treating pediatric patients with systemic mastocytosis are described by administering midostaurin. | 2021-03-18 |
20210077504 | Dry Powder Treprostinil for the Treatment of Pulmonary Hypertension - A dry powder inhalation treatment for pulmonary arterial hypertension includes a dose of dry particles comprising greater than 25 micrograms of treprostinil enclosed in a capsule. The dry particles can include treprostinil, a wetting agent, a hydrophobicity modifying agent, a pH modifying agent and a buffer. A method of treating a patient having pulmonary arterial hypertension includes providing a patient a dry powder inhaler, providing the patient at least one capsule for use in the dry powder inhaler, the capsule including at least 25 micrograms of treprostinil. | 2021-03-18 |
20210077505 | METHOD TO ENHANCE TISSUE REGENERATION - The present invention provides for compositions and methods for modulating tissue growth using tissue growth modulators, which are agents that either enhance or inhibit tissue growth as desired by a particular indication by modulating the PG or Wnt signaling pathways, or employing modulators of both PG and Wnt signaling pathways for a synergistic effect or highly selective effect. | 2021-03-18 |
20210077506 | TREATMENT OF ALLERGIC RHINITIS USING A COMBINATION OF MOMETASONE AND OLOPATADINE - The present invention relates to a method of treating allergic rhinitis in a subject (e.g., a pediatric human subject) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt. | 2021-03-18 |
20210077507 | TWO COMPONENT COMPOSITIONS - The present invention relates to a novel two-component system comprising acetylsalicylic acid (ASA) and which is particularly useful in providing an aqueous solution of ASA for immediate peroral administration. | 2021-03-18 |
20210077508 | INHIBITORS OF RAC1 AND USES THEREOF FOR INDUCING BRONCHODILATATION - The present invention concerns a compound having the following formula (I): wherein: —A is in particular —N(R′ | 2021-03-18 |
20210077509 | COMPOSITIONS FOR THE IMPROVED TREATMENT OF ACNE AND RELATED DISORDERS - Methods of treatment and dosage regimes using hydrophobic gel or foam composition comprising a tetracycline antibiotic in treating or alleviating a disorder including, acne, acne related symptoms, a tetracycline antibiotic responsive acne related disorder, skin disorder caused by a bacteria, and a tetracycline antibiotic responsive sebaceous gland disease, | 2021-03-18 |
20210077510 | COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY - The invention relates to methods of treating cancer, with a combination of an arginase inhibitor and a chemotherapeutic agent. The invention further relates to methods of assessing efficacy of a cancer treatment by measuring arginine levels in a tumor. | 2021-03-18 |
20210077511 | SUBSTITUTED 6-MEMBERED ARYL OR HETEROARYL ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS - present disclosure relates to compounds of formula (I) that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation. | 2021-03-18 |
20210077512 | NUTRITIONAL FORMULATIONS INCLUDING HUMAN MILK OLIGOSACCHARIDES AND ANTIOXIDANTS AND USES THEREOF - Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases. | 2021-03-18 |
20210077513 | SYNTHETIC COMPOSITION AND METHOD FOR MODULATING BRAIN FUNCTION AND BEHAVIOUR - A synthetic composition for use in improving one or more co-morbid mental disorder symptoms of a patient with IBS, characterised in that the composition contains an effective amount of one or more neutral human milk oligosaccharides, is disclosed. | 2021-03-18 |
20210077514 | Nutraceutical Composition for Improving Overall Health - A nutraceutical composition is provided. The nutraceutical composition includes nicotinamide mononucleotide and one or more compounds selected from a group consisting astaxanthin, berberine, pterstobline, resveratrol, metformin, wherein proportion of the nutraceutical composition comprises 15.28 to 66.67% w/w nicotinamide mononucleotide; 0.23 to 3.33% w/w astaxanthin; 50 to 61.35% w/w berberine; 7.12 to 33.33% w/w pterstobline; 23.47 to 81.45% w/w resveratrol; and 34.43 to 56.98% w/w metformin. The present disclosure provides various advantages, including but not limited to, efficiency with respect to cell absorption and synergistic effect in terms of therapeutic efficacy. | 2021-03-18 |
20210077515 | COMPOSITIONS CONTAINING BETA-NICOTINAMIDE MONONUCLEOTIDE AND CORDYCEPS SINENSIS AND USE THEREOF - The invention discloses a composition containing β-nicotinamide mononucleotide and | 2021-03-18 |
20210077516 | VAGINAL COMPOSITION AND USE THEREOF - A method of treating or preventing a vaginal disease and/or a vaginal discomfort in a patient in need thereof, the method comprising administering a vaginal composition comprising isomaltulose to the vagina of the patient to restore and/or maintain Lactobacilli in the vagina, and/or to restore and/or maintain the vaginal acidity, wherein the content of the isomaltulose ranges from 0.05% (w/w) to 20.0% (w/w). | 2021-03-18 |
20210077517 | Edible Energy Composition - The disclosure relates to an edible energy composition that provides physical and mental benefits when ingested. | 2021-03-18 |
20210077518 | POLYMORPHIC COMPOUNDS AND USES THEREOF - The present invention provides compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries. | 2021-03-18 |
20210077519 | PRODRUGS OF DEOXYNUCLEOSIDES FOR TREATMENT OF DISEASES CASED BY UNBALANCED NUCLEOTIDE POOLS - Deoxynucleotide prodrugs for treatment of diseases characterized by unbalanced nucleotide pools are provided herein. | 2021-03-18 |
20210077520 | VESICLES COMPRISING A PTEN INHIBITOR AND USES OF SAME - The present invention provides pharmaceutical compositions comprising membrane vesicles, including extracellular vesicles including those referred to as exosomes, loaded with an exogenous Phosphatase and tensin homolog (PTEN) inhibitor. Methods of treating neurological diseases, disorders or conditions using the extracellular vesicles are provided. Isolated extracellular vesicles loaded with an exogenous Phosphatase and tensin homolog (PTEN) inhibitor are provided as well. | 2021-03-18 |
20210077521 | NOVEL BIFIDOBACTERIUM BIFIDUM STRAIN AND STRAIN-DERIVED POLYSACCHARIDE - The present invention relates to a | 2021-03-18 |
20210077522 | HEPARIN COMPOSITION FOR TREATING ISCHEMIA - A pharmaceutical composition for treating an ischemic tissue, comprising: a core component and a matrix component, wherein the core component includes a heparin or derivative thereof and the matrix component includes a hyaluronan or derivative thereof, the pharmaceutical composition having a viscosity greater than 10 mPa-s. | 2021-03-18 |
20210077523 | HIGH MOLECULAR WEIGHT HYALURONIC ACID FOR TREATMENT AND PREVENTION OF SEVERE OCULAR SURFACE DISEASE - The invention concerns a method for reducing, preventing, or delaying the onset of severe ocular surface disease, or preventing or delaying the progression of mild or moderate ocular surface disease to severe ocular surface disease, by topically administering a fluid comprising high molecular weight hyaluronic acid to the ocular surface of the eye of a human or non-human animal subject, wherein the hyaluronic acid has an intrinsic viscosity of >2.5 m | 2021-03-18 |
20210077524 | INTRADIALYTIC USE OF SODIUM NITRITE - Provided herein are methods for maintaining physiological levels of nitrite in a subject undergoing hemodialysis. Also provided herein are methods of administering pharmaceutically acceptable sodium nitrite to a subject undergoing hemodialysis. | 2021-03-18 |
20210077525 | METHOD FOR BONE TISSUE REGENERATION IN EXPERIMENTS - The invention relates to the treatment of different bone injuries, particularly fractures and fissure fractures. In order to reduce the time taken for bone tissue to regenerate at the site of damage, a method is used for regenerating bone tissue by fixing fragments of the damaged bone with a plaster cast or a bandage made of a polymer material and introducing into the fracture zone an aqueous solution containing 1-hydroxyethylidene diphosphonic acid in an amount of (1.80-2.06) g/l, anhydrous calcium chloride in an amount of (1.44-2.22) g/l, gadolinium (III) nitrate hexahydrate in an amount of (0.30-0.40) g/l and dysprosium (III) chloride hexahydrate in an amount of (0.038-0.076) g/l, with a pH of (7.3-7.8), wherein, prior to being introduced into the fracture zone, the above solution is brought to a temperature of (30-100°) C., is held at this temperature for (1-48) hours and is then cooled to room temperature. | 2021-03-18 |
20210077526 | SUB-NANOMETER GOLD STICKER AND METHODS FOR PROTECTING AGAINST ENDOTOXIN-INDUCED SEPSIS THEREOF - A sub-nanometer gold sticker for blocking efficiently endotoxin activity to protect against sepsis is disclosed. The sub-nanometer gold sticker comprises a gold nanocluster that serves as a flake-like substrate and a coating of short alkyl motifs that act as an adhesive, allowing the sub-nanometer gold sticker to dock with LPS by compacting the intramolecular hydrocarbon chain-chain distance (d-spacing) of lipid A, an endotoxicity active site that can cause overwhelming cytokine induction resulting in sepsis progression. Methods of blocking endotoxin activity, and suppressing pro-inflammatory cytokines are also disclosed. Also disclosed is a method of protecting against endotoxin-induced sepsis via increasing critical micelle concentration for the inhibition of LPS non-lamellar aggregation. | 2021-03-18 |
20210077527 | UNIVERSAL DONOR SELECTION METHOD TO IDENTIFY NK-CELL-DONORS - Described herein are compositions comprising universal donor natural killer (NK) cells, populations of such cells, methods of obtaining and preparing such cells, and methods of use of such cells and compositions in medical treatment of cancers and infectious disease. | 2021-03-18 |
20210077528 | Modified Cell with Enhanced Functionality and Cellular Therapy thereof - Embodiments relate to a modified cell comprising a polynucleotide encoding a dominant negative form of Death receptor 5 (DR5). In embodiments, the modified cell further comprises a chimeric antigen receptor (CAR) and/or a modified TCR. | 2021-03-18 |
20210077529 | T-CELL EXHAUSTION, METHODS & COMPOSITIONS RELATING THERETO - The present invention provides methods for the induction and monitoring of T cell exhaustion in vitro. The methods are effective for both human and non-human T cells, and for both antigen-specific and polyclonal T cells. The present invention also provides methods to screen for and/or evaluate pharmacologic agents that can either induce or reverse T cell exhaustion. The present invention also provides certain agents that can reverse T cell exhaustion. | 2021-03-18 |
20210077530 | AUTO/ALLO-IMMUNE DEFENSE RECEPTORS FOR THE SELECTIVE TARGETING OF ACTIVATED PATHOGENIC T CELLS AND NK CELLS - Embodiments of the disclosure concern engineered auto/allo-immune defense receptor (ADR)-expressing T cells that selectively target activated T cells, including pathogenic T cells, to incapacitate them. The chimeric receptors comprise moieties for targeting 4-1BB, 0X40, and CD40L, for example, whose expression is indicative of activated T cells. In particular embodiments, there are methods of preventing or treating conditions associated with activated T cells using adoptive T-cell transfer of cells encoding the ADRs. | 2021-03-18 |
20210077531 | METHOD FOR PREPARING CAR-T CELL WITH TCM AS MAIN ACTIVE COMPONENT AND USE THEREOF - A method for increasing the proportion of a central memory T cell (Tcm) subset in a CAR-T cell product includes adding an artificial antigenic epitope in a CAR, and activating a CAR-T by the artificial antigenic epitope, wherein the artificial antigenic epitope does not exist in other domains or segments of the CAR. A method for preparing a CAR-T cell includes: introducing the CAR into a T cell; and culturing the CAR-introduced T cell, and performing specific activation in the culture process. The preparation method can not only increase the proportion of CAR-positive T cells in the product, but also can achieve specific in vitro amplification of the Tcm subset in the CAR-positive T cells, and significantly increases the proportion of Tcm in a final product. Clinical trials show that the CAR-T cells have significantly improved amplification capacity in vivo, and improved clinical safety and effectiveness. | 2021-03-18 |
20210077532 | Modified Cell Expansion and Uses Thereof - The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion and/or maintenance in vivo and/or in vitro. For example, a method of enhancing T cell-based therapy comprises administering genetically modified T cells comprising a first chimeric antigen receptor (CAR) and a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR binds a surface molecule or antigen of a white blood cell. | 2021-03-18 |
20210077533 | MULTILAYERED BLOOD PRODUCT - A blood product ( | 2021-03-18 |
20210077534 | COMPOSITIONS FOR ESTABLISHING MIXED CHIMERISM AND METHODS OF MANUFACTURE THEREOF - The invention provides compositions for establishing mixed chimerism in a subject. The compositions include CD34 | 2021-03-18 |
20210077535 | NEURAL STEM CELL DELIVERY OF THERAPEUTIC AGENTS - The disclosure provides, inter alia, neural stem cells comprising exogenous nucleotides, vesicles comprising exogenous nucleotides, and methods for treating diseases and disorders, such as cancer, neurodegenerative diseases, inflammatory diseases, and viral diseases, using the neural stem cells, vesicles, and pharmaceutical compositions comprising them. | 2021-03-18 |
20210077536 | NON-NATURALLY OCCURING THREE-DIMENSIONAL (3D) BROWN ADIPOSE-DERIVED STEM CELL AGGREGATES, AND METHODS OF GENERATING AND USING THE SAME - The present application provides non-naturally occurring 3D brown adipose-derived stem cell (BADSC) aggregates, methods of making the 3D BADSC aggregates, and methods of using the 3D BADSC aggregates. | 2021-03-18 |
20210077537 | CONDITIONED MEDIUM FROM HUMAN ADULT LIVER STEM CELLS AND ITS USE IN THE TREATMENT OF LIVER DISORDERS - The invention relates to cell-free compositions obtained by culturing adult-derived human liver stem/progenitor cells (ADHLSC) in cell culture medium and isolating the resulting conditioned medium (ADHLSC-CM) that has advantageous properties, such as anti-fibrotic effects. ADHLSC-CM, compositions based on ADHLSC-CM, and other related and derived products, can be used in cell culture processes or as a medicament, more particularly for the treatment of diseases involving organ injury, organ failure, in organ or cell transplantation or the pathological disruption, inflammation, degeneration, and/or proliferation of cells within a tissue or an organ, in particular within liver. | 2021-03-18 |
20210077539 | PROCESS FOR THE MANUFACTURE OF ENRICHED PHOSPHOLIPID COMPOSITIONS - It is provided a process for generating enriched phospholipid compositions from raw krill oil, where such processes may be batchwise, continuous, of include both batchwise steps and continuous steps. The present technology provides high quality enriched phospholipid compositions from such methods. Moreover, the continuous process provides a significantly higher throughput compared to a batch process while concurrently providing products of equal or greater quality. | 2021-03-18 |
20210077540 | BIOACTIVE GREEN-LIPPED MUSSEL EXTRACTS AND USES THEREOF - A biologically active non-lipid extract comprising of an isolated molecular weight fraction of <10 kDa or <1 kDa derived from New Zealand green-lipped mussels ( | 2021-03-18 |
20210077541 | MICROBIAL CONSORTIA - Provided herein are microbial strains isolated de novo. In some instances, the bacterial strains include genera, species, and/or strains of | 2021-03-18 |
20210077542 | USE OF GENETICALLY ENGINEERED BACTERIUM OF ATTENUATED SALMONELLA TYPHIMURIUM IN FOR TREATING LIVER CANCER - Provided is use of a genetically engineered bacterium of attenuated | 2021-03-18 |
20210077543 | PROBIOTIC BACTERIAL STRAINS PRODUCING ANTIMICROBIAL PROTEINS AND COMPOSITIONS COMPRISING THESE FOR USE IN THE TREATMENT OF DIARRHEAL AND OTHER MICROBIAL DISEASES - The present invention is directed to a bacterial, preferably probiotic bacterial peptidoglycan hydrolase (PGH), a peptidoglycan hydrolase (PGH)-comprising bacterial, preferably probiotic bacterial strain or a peptidoglycan hydrolase (PGH)-comprising composition for use in the therapeutic or prophylactic treatment of a bacterial infection, preferably for the treatment of a bacterial infection resulting in diarrhea. Further aspects of the present invention relate to corresponding methods for preparing a medicament and to a corresponding method of treatment. | 2021-03-18 |
20210077544 | SANITIZER COMPOSITION WITH PROBIOTIC/PREBIOTIC ACTIVE INGREDIENT - A topical sanitizing composition for restoring skin's natural balance of bacteria is provided. The topical sanitizing composition includes about 0.02 wt. % to 10.0 wt. % of an active ingredient, at least about 40 wt. % of one or more C | 2021-03-18 |
20210077545 | BACILLUS COMPOSITIONS AND METHODS OF USE WITH RUMINANTS - strains, compositions and methods are disclosed for reducing growth of microorganisms in a feed. | 2021-03-18 |
20210077546 | COMPOSITIONS AND METHODS FOR INCREASING BUTYRATE PRODUCTION - Provided herein are compositions and methods for increasing butyrate production in a subject. In particular, provided herein are compositions, probiotic compositions, and combinations thereof that promote butyrate production in a subject. | 2021-03-18 |
20210077547 | SPORE-BASED PROBIOTIC COMPOSITION FOR MODULATION OF MICROBIOME IN HUMANS - A spore-based probiotic composition is provided that comprises at least one viable probiotic microorganism having a biological or therapeutic effect on microbiome in humans. One exemplary composition contains five different strains of | 2021-03-18 |
20210077548 | Sleep-Promoting Composition, and Medical Composition and Food and Beverage Composition Using Said Sleep-Promoting Composition - Provided is a novel sleep-promoting composition. | 2021-03-18 |
20210077549 | METHODS AND PROBIOTIC COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISEASES AND DISORDERS - Disclosed are methods and probiotic compositions for the treatment of a metabolic disease or disorder such as, e.g., obesity, type 2 diabetes, or fatty liver. In some embodiments, heat-inactivated | 2021-03-18 |
20210077550 | LACTOBACILLUS PARACASEI STRAIN AND USE THEREOF - Human-derived probiotic strains | 2021-03-18 |
20210077551 | THERAPEUTIC BACTERIOPHAGE COMPOSITIONS FOR TREATING STAPHYLOCOCCUS INFECTION - The present disclosure relates to a bacteriophage composition comprising one or more (suitably two or more, or three) obligately lytic bacteriophages capable of infecting and lysing | 2021-03-18 |
20210077552 | MUTANT ADENO-ASSOCIATED VIRUS VIRIONS AND METHODS OF USE THEREOF - The present invention provides mutant adeno-associated virus (AAV) that exhibit altered capsid properties, e.g., reduced binding to neutralizing antibodies in serum and/or altered heparin binding and/or altered infectivity of particular cell types. The present invention further provides libraries of mutant AAV comprising one or more mutations in a capsid gene. The present invention further provides methods of generating the mutant AAV and mutant AAV libraries, and compositions comprising the mutant AAV. The present invention further provides recombinant AAV (rAAV) virions that comprise a mutant capsid protein. The present invention further provides nucleic acids comprising nucleotide sequences that encode mutant capsid proteins, and host cells comprising the nucleic acids. The present invention further provides methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof. | 2021-03-18 |
20210077553 | COMPOSITIONS FOR DRG-SPECIFIC REDUCTION OF TRANSGENE EXPRESSION - Provided herein is a recombinant AAV (rAAV) comprising an AAV capsid and a vector genome packaged therein, wherein the vector genome comprises an AAV 5′ inverted terminal repeat (ITR), an engineered nucleic acid sequence encoding a gene product for expression in target cells, and miRNA target sequences which selectively repress expression in dorsal root ganglion (DRG) cells. Also provided is a pharmaceutical composition comprising a rAAV as described herein in a formulation buffer, and a method of treating a human subject with CNS-targeted gene therapy while selectively preventing expression in DRG cells. | 2021-03-18 |
20210077554 | Methods of Neoplasm Treatment Utilizing Complementary Oncolytic Viruses and CAR T-Cells - Methods of treatment utilizing complimentary transgenic oncolytic virus and engineered CAR T-cells are provided. Oncolytic viruses are engineered such that they can express an ectopic antigen on neoplastic cells. CAR T-cells are engineered to recognize the ectopic antigen are utilized in various methods of treatment. Accordingly, a transgenic oncolytic virus can be administered to a neoplasm to induce expression of an ectopic antigen and then that neoplasm can be treated with a complimentary CAR T cells engineered to recognize the ectopic antigen to induce an immune response against the neoplasm, resulting in neoplastic cell death and/or clearance. | 2021-03-18 |
20210077555 | METHOD FOR REDUCING TOTAL GAS PRODUCTION AND/OR METHANE PRODUCTION IN A RUMINANT ANIMAL - The present invention relates to a method of reducing total gas production and/or methane production in a ruminant animal. | 2021-03-18 |
20210077556 | VE-CADHERIN EXPRESSION PROMOTING AGENT AND/OR INTEGRIN a5 EXPRESSION PROMOTING AGENT - The purpose of the present invention is to provide a substance related to the stabilization of capillary blood vessels. This invention is based on the discovery that an extract from a plant selected from the group consisting of | 2021-03-18 |
20210077557 | ESSENTIAL ELEMENT MANAGEMENT - The invention extends the utility of apparatus used to extract medicinal | 2021-03-18 |